An overview of the Protective-1 trial of single-agent plinabulin vs pegfilgrastim after docetaxel in patients with advanced breast cancer, advanced non–small cell lung cancer, and hormone-refractory prostate cancer.
Targeted Oncology
Articles by Targeted Oncology
The rationale for studying plinabulin, a first-in-class selective immunomodulating microtubule binding agent, for the prevention of chemotherapy-induced neutropenia.
Strategies for prophylaxis against chemotherapy-induced neutropenia in the setting of metastatic disease.
Limitations of current therapies available for the prevention and management of chemotherapy-induced neutropenia.
Current mitigation and management strategies for chemotherapy-induced neutropenia.
John Mascarenhas, MD, and Ruben Mesa, MD, share insights on the evolving treatment landscape of myelofibrosis.
Recommendations for preventing and mitigation infection risk in patients with chemotherapy-induced neutropenia in the adjuvant setting.
Implications of severity and sequelae of chemotherapy-induced neutropenia for disease management.
Drs Neeraj Agarwal and Petros Grivas comment on biomarkers and novel therapies under investigation for advanced urothelial carcinoma and remark on the next steps for treating patients with antibody-drug conjugates.
Expert hematologist-oncologists comment on the optimization of JAK inhibitor therapies, including ruxolitinib, momelotinib, fedratinib, and pacritinib, in myelofibrosis treatment.
Strategies to help manage treatment-related toxicities to novel therapies used in the management of advanced urothelial carcinoma.
Drs Ruben Mesa and John Mascarenhas review therapies and drugs in development for the treatment of myelofibrosis as seen in the COMFORT, JAKARTA, MOMENTUM, PACIFICA, and PERSIST trials.
The importance of collecting patient-reported outcomes data in urothelial carcinoma as it relates to novel treatment selection.
Considerations for treatment selection for chemotherapy-induced neutropenia.
General considerations surrounding the risk of chemotherapy-induced neutropenia in solid tumors.
John Mascarenhas, MD, and Ruben Mesa, MD, share insights on the role of IRAK signaling on the disease biology of myelofibrosis.
Advice regarding patient selection for sacituzumab govitecan and the management of treatment-related adverse events.
Recommendations regarding how to best integrate newer therapies, including antibody-drug conjugates, into treatment plans for patients with advanced urothelial carcinoma.
Hematology/oncology experts review the role of JAK2 allele burden in patients and its effect on treatment outcomes for myelofibrosis.
The rationale for treating patients with advanced urothelial carcinoma with sacituzumab govitecan, a novel antibody-drug conjugate now approved that targets Trop-2.
Ruben Mesa, MD, and John Mascarenhas, MD, discuss whether therapies with a clinically meaningful impact on myelofibrosis may have a survival advantage for patients.
Expert hematologist/oncologists comment on the value of reducing fibrosis as a potential goal of therapy when treating patients with myelofibrosis.
Reactions to the availability of antibody-drug conjugates as later-line therapy for patients with metastatic urothelial carcinoma, and potential considerations for adopting enfortumab vedotin into clinical practice.
Drs John Mascarenhas and Ruben Mesa review unmet needs and challenges in treating myelofibrosis.
Second-line treatment approaches available for metastatic urothelial carcinoma and considerations for switching therapies vs re-challenging with prior therapy.
What to know regarding molecular testing assays used to assess patients with metastatic urothelial carcinoma.
Ruben Mesa, MD, and John Mascarenhas, MD, review the patient selection of extended molecular panels and the appropriate interval for molecular profiling for the management of myelofibrosis.
Loretta Nastoupil, MD, and John Burke, MD, discuss the future of the therapeutic landscape for patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.
Experts discuss the LOTIS-2 trial that studied loncastuximab tesirine, a CD19-targeted monoclonal antibody for treating patients with relapsed/refractory diffuse large B-cell lymphoma.
First-line treatment options available for patients with metastatic urothelial carcinoma and variables that impact treatment selection.